Cargando…
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
BACKGROUND: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. METHODS: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European S...
Ejemplares similares
-
237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries
por: Cortellini, A., et al.
Publicado: (2022) -
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022) -
LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases
por: Romano, E., et al.
Publicado: (2022) -
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
por: Martin, P., et al.
Publicado: (2023) -
1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)
por: Romano, E., et al.
Publicado: (2021)